In8Bio Inc is a biotechnology company focused on developing innovative therapies for cancer treatment
The company specializes in the advancement of cell-based therapies, particularly utilizing T cell engineering to target and eliminate cancer cells. By harnessing the power of the immune system, In8Bio aims to create effective and personalized treatment options for patients with various types of malignancies. Their research and development efforts are centered around developing cutting-edge approaches that enhance the efficacy and safety of immunotherapies, contributing to the evolving landscape of cancer treatment.
IN8bio's nsCAR platform, INB-300. Presented at AACR 2024, new preclinical data highlights its superior selectivity in targeting leukemia cells while sparing healthy tissue. Experience a potential wider therapeutic window without compromising efficacy.
Shares of PriceSmart, Inc. (NASDAQPSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter.
IN8bio (NASDAQINAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these cells to effectively target and eliminate cancer cells in both solid and hematological tumors.
Shares of Despegar.com, Corp. (NYSEDESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The company said it now sees revenue of $690 million to $700 million, versus previous forecast of $670 million to $700 million.
